Products with Anticancer bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN1244 | Ginsenoside F1 |
| Ginsenoside has been reported to suppress platelet aggregation and to reduce gap junction-mediated intercellular communication, also as a novel anti-skin cancer drug with anti-proliferative and anti-migration features. Ginsenoside F1 has a potential for industrial cosmetic materials, it also has inhibitory effect of elastase and tyrosinase, it significantly reduces ultraviolet-B-induced cell death by maintaining constant levels of Bcl-2 and protects HaCaT cells from apoptosis caused by ultraviolet B irradiation. | |
| BCN1245 | Ginsenoside F2 |
| Ginsenoside F2, an autophagic initiater, which has anti-cancer, and anti-obesity activities. Ginsenoside F2 inhibited the growth and invasion of cancer, and activated the intrinsic apoptotic pathway and mitochondrial dysfunction. Ginsenoside F2 suppresses hair cell apoptosis and premature entry to catagen more effectively than finasteride, it decreases the expression of TGF-β2 and SCAP proteins, the factors in the SCAP pathway could be targets for hair loss prevention drugs. | |
| BCN1246 | Ginsenoside Compound K |
| Ginsenoside compound K (C-K) is a metabolite of the protopanaxadiol-type saponins of Panax ginseng C.A. Meyer, has long been used to treat against the development of cancer, inflammation, allergies, and diabetes; C-K acts as a unique HUVEC migration inhibitor by regulating MMP expression, as well as the activity of SPHK1 and its related sphingolipid metabolites. C-K exhibits anti-inflammatory effects by reducing iNOS and COX-2, C-K exhibits an inhibition against the activity of CYP2C9 and CYP2A6 in human liver microsomes with IC50s of 32.0±3.6 μM and 63.6±4.2 μM, respectively. C-K promotes Aβ clearance by enhancing autophagy via the mTOR signaling pathway in primary astrocytes. | |
| BCN1252 | Isolinderalactone |
| Isolinderalactone shows anti-inflammatory and anticancer capacity, it induces apoptosis in MDA-MB-231 cells and suppresses STAT3 signaling pathway through regulation of SOCS3 and miR-30c, may become a novel treatment for triple-negative breast cancer in the future; it exhibits moderate iNOS inhibitory activity, with the IC50 value of 0.30 uM. | |
| BCN1269 | Sarsasapogenin |
| Sarsasapogenin has antidiabetic, improving memory, antidepressant, anti-oxidative, anticancer and anti-inflamatory activities. It can effectively promote the proliferation,differentiation and mineralization of osteoblasts cultured in vitro, it also can inhibit the generation of osteoclasts from marrow cells. Sarsasapogenin potently inhibited NF-κB and MAPK activation, as well as IRAK1, TAK1, and IκBα phosphorylation in LPS-stimulated macrophages. | |
